Par Pharmaceutical Companies Q1 FY12: revenue $271.5M; diluted EPS −$0.79

Key figures from this report

These are the numbers Par Pharmaceutical Companies reported for Q1 FY12, the quarter ended Mar 31, 2012, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$271.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Net income−$28.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
3. Diluted EPS−$0.79No year-earlier figure tagged10-Q income statement, on EDGAR
4. Cash and cash equivalents$156.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations$26.4MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR